Bluejay Diagnostics, Inc.

Snapshot

Bluejay is a pre-revenue diagnostics company with $0 in sales for three straight fiscal years and a $6.8M net loss in FY 2025. It burned $6.2M in free cash flow and held $9.6M in cash as of mid-2026, boosted by a June private placement.

What's Happening Right Now

• Wed 9th Sep '26 · Going concern: Bluejay's Q2 2026 10-Q discloses substantial doubt about its ability to continue as a going concern, with $9.6M in cash funding operations only into Q2 2027 and a need to raise $10-14M more by the end of fiscal 2027, with Chapter 7 liquidation possible if financing fails.
• Wed 9th Sep '26 · Cash raise: Bluejay ended Q2 2026 with about $9.6M in cash, up from $5.2M at year-end 2025, after a June 2026 private placement brought in roughly $7.6M net; management says this funds operations only into Q2 2027.
• Wed 9th Sep '26 · Partnership: Bluejay signed a two-year distribution deal with Lovell Government Services to sell into VA, DoD, and IHS federal healthcare channels, though no revenue can flow until the Symphony platform gets FDA clearance.
• Sun 2nd Aug '26 · Clinical trial: Bluejay completed enrollment of 750 patients in its SYMON-II study for the investigational Symphony IL-6 sepsis test, with a 17% observed mortality rate, ahead of a planned FDA 510(k) submission.
• Fri 26th Jun '26 · Dilution filing: Bluejay filed a prospectus for resale of up to 11.2 million warrant-linked shares tied to its June 2026 private placement, alongside disclosure of a cumulative 1-for-32,000 reverse split executed between 2023 and January 2026 and an auditor going-concern warning.